| Drug Name: | Methsuximide (77-41-8) |
|---|---|
| PubChem ID: | 6476 |
| SMILES: | CC1(CC(=O)N(C1=O)C)C2=CC=CC=C2 |
| InchiKey: | AJXPJJZHWIXJCJ-UHFFFAOYSA-N |
| Therapeutic Category: |
| Molecular Weight (dalton) | : | 203.241 |
| LogP | : | 1.333 |
| Ring Count | : | 1 |
| Hydrogen Bond Acceptor Count | : | 2 |
| Hydrogen Bond Donor Count | : | 0 |
| Total Polar Surface Area | : | 37.38 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Phenobarbital (50-06-6) | Increased The Serum Levels Of The Active Metabolite Of Mesuximide! N-Desmethylmesuximid | Synergistic | phenobarbital compete with mesuximide for the same metabolic mechanisms (hydroxylation) in the liver. As a result metabolised more slowly and therefore their levels increase | Pharmacological interactions of mesuximide with phenobarbital and phenytoin in hospitalized epileptic patients |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Dangerous Side Effects | Cytochrome P450 2C19 (P33261) | Methsuximide inhibits CYP2C19-mediated S-mephenytoin 4#-hydroxylation@ which may increase the level of mephenytoin in blood and cause dangerous side effects [ ADR Type 4 ] | The role of S-mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|---|---|---|---|
| N-desmethyl metabolite | Ataxia | Plasma levels of methsuximide and N?desmethylmethsuximide during methsuximide therapy |
This panel provides information on drug category